Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1Bronchiolitis Obliterans Syndrome 1Anemia, Refractory, with Excess of Blasts 1

Interventions

nilotinib 3asciminib 3Imatinib Mesylate 3bosutinib 2Dasatinib 2ruxolitinib 1ponatinib 1milatuzumab 1lonafarnib 1Vision, Ocular 1Panobinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bronchiolitis Obliterans Syndrome × lonafarnib × Myeloid × Clear all
NCT00038597 2018-10-30

Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)

M.D. Anderson Cancer Center

Phase 2 Completed
13 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡